AstraZeneca (AZN) Stock Price & Analysis

AZN$179.36-2.91 -1.60%
Drug Manufacturers - GeneralMega CapHigh Quality
Compare
Market cap$278.16BEnterprise value$311.89BRevenue (TTM)$62.17BMarket positionTop 5%

Score

55
Neutral
Value
45
Quality
63
Growth
56

AI Analysis

Snapshot

AstraZeneca is a mixed profile at 55/100 — Value 45, Growth 56, Quality 63. Under the hood: P/E 25.9, about 27% below its own multi-year median, plus revenue compounding ~10% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

45
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

56
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

63
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

AstraZeneca PLC (AZN) last printed $179.36. Equity value is $278.16B. Trailing earnings multiple 25.20. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$23B$22.46B$22.09B$24.38B$26.62B$37.42B$44.35B$45.81B$54.07B$58.74B

About

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

AstraZeneca (AZN) Stock Price & Analysis

AZN price $179.36 -2.91 -1.60%

Ticker
AZN
Price
$179.36
Change
-2.91 -1.60%
Market cap
$278.16B
P/E
25.20
Forward P/E
16.20
Dividend yield
1.72%
Beta
0.21
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
55
Value
45
Quality
63
Growth
56

Stocklytics score rationale: value 45, quality 63, growth 56.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener